Literature DB >> 9323280

Post-dysenteric hemolytic uremic syndrome in children during an epidemic of Shigella dysentery in Kwazulu/Natal.

R Bhimma1, N C Rollins, H M Coovadia, M Adhikari.   

Abstract

We report 81 of 107 cases of hemolytic uremic syndrome (HUS), admitted between July 1994 and February 1996, following an outbreak of Shigella dysenteriae type 1 dysentery in Kwazulu/Natal. All patients, excluding 1, were black with a mean age of 38 months (range 1-121); 50 (61.7%) were males. The mean duration of dysentery was 11.3 days (range 1-41) and HUS 15 days (range 1-91). Most patients had acute oliguric renal failure (90.1%), 42 (51.6%) required peritoneal dialysis. Complications included encephalopathy 30 (37.0%), convulsions 12 (14.8%) and hemiplegia 2 (2.3%), gastrointestinal perforation 8 (9.9%), protein losing enteropathy 26 (32.1%), toxic megacolon 4 (4.9%), rectal prolapse 5 (6.2%), hepatitis 11 (13.6%), myocarditis 5 (6.2%), congestive cardiac failure 3 (3.7%), cardiomyopathy 3 (3.7%), infective endocarditis 1 (1.2%), septicemia 15 (18.5%), disseminated intravascular coagulation 17 (21%). Leukemoid reactions were found in 74 (91.3%) patients, hyponatremia in 56 (69.1%), and hypoalbuminemia in 67 (82.7%). Stool culture for Shigella dysenteriae type I was positive in only 7 (8.6%) patients; Shiga toxin assays were not performed. Outcome was as follows: recovery 32 (39.5%), impaired renal function 8 (9.9%), chronic renal failure 26 (32.1%), end-stage renal disease 1 (1.2%), and death 14 (17.3%) patients.

Entities:  

Mesh:

Year:  1997        PMID: 9323280     DOI: 10.1007/s004670050338

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  16 in total

1.  The spectrum of chronic kidney disease (stages 2-5) in KwaZulu-Natal, South Africa.

Authors:  Rajendra Bhimma; Miriam Adhikari; Kareshma Asharam; Catherine Connolly
Journal:  Pediatr Nephrol       Date:  2008-06-12       Impact factor: 3.714

2.  Shigella: A Highly Virulent and Elusive Pathogen.

Authors:  Mussaret Bano Zaidi; Teresa Estrada-García
Journal:  Curr Trop Med Rep       Date:  2014-06-01

3.  Protective efficacy and pharmacokinetics of human/mouse chimeric anti-Stx1 and anti-Stx2 antibodies in mice.

Authors:  Angela R Melton-Celsa; H M Carvalho; Claire Thuning-Roberson; A D O'Brien
Journal:  Clin Vaccine Immunol       Date:  2015-02-25

4.  A time for reappraisal of "atypical" hemolytic uremic syndrome: should all patients be treated the same?

Authors:  Rebecca L Ruebner; Bernard S Kaplan; Lawrence Copelovitch
Journal:  Eur J Pediatr       Date:  2012-06-07       Impact factor: 3.183

Review 5.  Catastrophic APS in the context of other thrombotic microangiopathies.

Authors:  Ignasi Rodríguez-Pintó; Gerard Espinosa; Ricard Cervera
Journal:  Curr Rheumatol Rep       Date:  2015-01       Impact factor: 4.592

6.  Characteristics and outcome of hemolytic uremic syndrome in Sudanese children in a single Centre in Khartoum State.

Authors:  Eltigani Mohamed Ahmed Ali; Nagmelddin Mohamed Abbakar; Mohamed Babikir Abdel Raheem; Rashid Abdelrahman Ellidir
Journal:  Sudan J Paediatr       Date:  2017

7.  Haemolytic uraemic syndrome in children admitted to a rural district hospital in Kenya.

Authors:  Ally Ibrahim Olotu; S Mithwani; C R J C Newton
Journal:  Trop Doct       Date:  2008-07       Impact factor: 0.731

Review 8.  Hemolytic uremic syndrome.

Authors:  Nur Canpolat
Journal:  Turk Pediatri Ars       Date:  2015-06-01

Review 9.  Part II. Analysis of data gaps pertaining to Shigella infections in low and medium human development index countries, 1984-2005.

Authors:  P K Ram; J A Crump; S K Gupta; M A Miller; E D Mintz
Journal:  Epidemiol Infect       Date:  2007-08-09       Impact factor: 2.451

10.  Hemolytic uremic syndrome: new developments in pathogenesis and treatment.

Authors:  Olivia Boyer; Patrick Niaudet
Journal:  Int J Nephrol       Date:  2011-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.